Table 3.
The comparison between Patients with CRRT and non-CRRT who were in AKI stage 3
| AKI stage 3 (N = 63) | CRRT (N = 32) | non-CRRT (N = 31) | p | |
|---|---|---|---|---|
| Male(%) | 57 (90.5) | 31 (96.9) | 26 (83.9) | 0.104 |
| Age(years) | 43 (37–50) | 42 (37–56) | 44 (36–48) | 0.527 |
| Blood routine and biochemical items | ||||
| Lymphocyte count(×109) | 0.5 (0.24–1.00) | 0.54 (0.34–1.05) | 0.5 (0.2–0.8) | 0.146 |
| Hemoglobin(g/L) | 91 (70.8–108) | 91 (71.8–109.5) | 89 (70.7–104.5) | 0.929 |
| Albumin(g/L) | 27.4 (23.8–31.7) | 30.3 (24.9–32.5) | 26.8 (22.3–30.2) | 0.027 |
| T-Bil (umol/L) | 8.7 (5.8–15.9) | 7.8 (5.1–14.5) | 11.4 (6.3–16.0) | 0.343 |
| Serum calcium(mmol/L) | 1.92 (1.71–2.09) | 2.0 (1.68–2.18) | 1.88 (1.74–2.03) | 0.221 |
| Lactate (mmol/L) | 2.8 (1.45–6.05) | 3.65 (1.55–7.15) | 2.1 (1.35–5.0) | 0.091 |
| Serum phosphate(mmol/L) | 1.11 (0.81–1.65) | 1.45 (0.81–1.88) | 1.02 (0.81–1.36) | 0.159 |
| LDH (U/L) | 450 (309.6–786.6) | 501 (281.6–1233) | 450 (321.2–663.2) | 0.336 |
| Items related to HIV infection | ||||
| CD4 counts at ICU admission(cells/ml) | 24 (8–86) | 37 (13–116) | 11 (5–36) | 0.009 |
| HIV viral load (copies/mL) | 1700 (90–249,112) | 1650 (0–174,710) | 37,444 (1142–335,614) | 0.116 |
| HAART(%) | 26 (41) | 10 (31) | 16 (51.6) | 0.052 |
| Complication | ||||
| PCP (%) | 30 (47.6) | 12 (37.5) | 18 (58.1) | 0.102 |
| Septic Shock(%) | 41 (65.1) | 19 (59.4) | 22 (71) | 0.245 |
| Multiple Organs Support Therapy | ||||
| The use of vasoactive agents(%) | 46 (73) | 22 (66.8) | 24 (77.4) | 0.349 |
| Duration of Mechanical ventilation (h) | 120 (7–240) | 142 (5–256) | 119 (14–212.5) | 0.825 |
| Severity of illness | ||||
| SOFA score at ICU admission (scores) | 9 (7–13) | 11 (7–14) | 9 (6–11) | 0.094 |
| APACHE-II score at ICU admission(scores) | 23 (19–33) | 28 (22–35) | 19 (18–30) | 0.015 |
| Outcome | ||||
| Death during in ICU | 34 (54) | 18 (56) | 14 (45.2) | 0.521 |
| Renal recovery | 17 (27.0) | 7 (21.9) | 10 (32.3) | 0.353 |
| Length of ICU stay (days), median (IQR) | 8 (5–14) | 8 (5–15) | 6 (5–14) | 0.679 |
| Length of hospital (days), median (IQR) | 16 (9–29) | 15 (7–21) | 17 (12–38) | 0.029 |
T-Bil Total bilirubin, HAART Highly Active Anti-Retroviral Therapy, PCP Pneumocystis carinii pneumonia, CRRT Continuous renal replacement therapy, ICU Intensive care unit, IQR Interquartile range, APACHE-II Acute physiology and chronic health evaluation, version II, SOFA Sequential organ failure assessment
p Value < 0.05 was considered significant and is highlighted in bold